TABLE 5.

RECOMMENDED AREAS FOR FUTURE SCP RESEARCH AND METHODOLOGICAL CONCERNS TO BE ADDRESSED

Content

1. When do survivors and providers prefer for SCP to be delivered?

2. How frequently do survivors and providers prefer for SCP to be delivered?

3. Which type of provider most effectively develops SCP?

4. Which type of provider most effectively delivers SCP?

Dissemination and implementation

1. What determines whether survivors and primary care providers receive and retain SCP?

2. Does a limited-content SCP template minimize resources required for SCP use?

3. Does a limited-content SCP template increase SCP use?

Outcomes

1. What are the “active ingredients” of effective transitions from treatment to follow-up care?

2. Are survivors who receive SCP more likely than survivors without SCP to get guideline-concordant care?

3. Are survivors who receive SCP less likely than survivors without SCP to receive duplicative services?

4. How confident are providers in managing survivors’ follow-up care?

5. What costs are associated with SCP use.

6. Which patient-, provider-, and cancer program-level variables are most relevant SCP-related outcomes?

Methodological concerns to be addressed

1. Biases associated with observational studies may be addressed by using RCT.

2. Inability to infer causality may be addressed with longitudinal studies.

3. Limited generalizability may be addressed with more diverse samples of cancer programs, providers, and survivors that reflect the diversity found in practice.

4. Concerns about validity and reliability may be addressed through systematic testing of data collection tools.

Abbreviations for all tables: ASCO, American Society of Clinical Oncology; BCS, breast cancer survivor; CCS, colorectal cancer survivor; IOM, Institute of Medicine; NCI, National Cancer Institute; PCP, primary care provider; RCT, randomized controlled trial; SCP, survivorship care plan; TS, treatment summary